1 day+2.88%
1 week-7.03%
Current month-7.74%
1 month+52.76%
3 months+81.49%
6 months+21.60%
Current year+11.19%
1 week 5.87
Extreme 5.87
6.66
1 month 3.95
Extreme 3.9467
7.78
Current year 3.1
Extreme 3.1
7.78
1 year 3.1
Extreme 3.1
7.78
3 years 3.1
Extreme 3.1
31.2
5 years 3.1
Extreme 3.1
214.1
10 years 3.1
Extreme 3.1
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 55 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 55 2024-05-14
Chairman 56 2024-09-03
Date Insider Type Main position Quantity % Market Cap. Importance
9/18/26 Sell

Chief Operating Officer

-6,850 0.3556%
9/18/26 Sell

Controller/Auditor

-4,077 0.2116%
9/18/26 Sell

Chief Executive Officer

-9,132 0.4741%
Change 5-day change 1-year change 3-year change Capi.($)
+2.88%-7.03%+33.04%-68.98% 15.72M
-2.69%-0.48%+53.97%+70.99% 66.33B
-0.92%+7.67%+12.64%+92.55% 60.62B
0.00%+0.39%+22.34%+90.83% 55.5B
+0.14%+2.35%+13.86%+106.64% 47.58B
-2.21%-2.47%+20.18%+32.24% 43.69B
-2.30%-10.40%+154.30%+725.54% 37.27B
+2.15%+1.42%+14.58%+54.23% 36.57B
-2.32%-2.24%+76.50%+54.55% 32.22B
+2.62%+5.90%-37.29%+393.72% 26.58B
Average -0.26%-0.66%+36.41%+155.23% 41B
Weighted average by Cap. -0.83%+0.20%+36.63%+155.24%
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in half-life-extended multispecific antibodies designed to deliver therapies. Through the proprietary INSPIRE platform, the Company combines complementary therapeutic mechanisms in fully IgG-based molecules designed for efficacy and extended exposure. Its lead program, PRA-216, is a novel IL-4Ra/TSLP bispecific antibody in Phase II development in asthma, chronic obstructive pulmonary disease, and atopic dermatitis, with a fourth Phase II study planned in eosinophilic esophagitis. In addition to PRA-216, the Company is advancing a wholly owned pipeline of additional INSPIRE-based multispecific programs across diseases with significant unmet need. Its second program is an IL-31 containing bispecific antibody being developed initially for atopic dermatitis. The Company is open to various partnering programs, including BDC-3042: P2-ready Dectin-2 Agonist mA, Preclinical CEA ISAC and Preclinical PD-L1 ISAC.
Employees
-
Date Price Change Volume
26-11-13 US$6.080 +2.88% 28,118
26-11-12 US$5.910 -5.59% 177,672
26-11-11 US$6.260 -0.63% 42,676
26-11-10 US$6.300 -2.02% 111,898
26-11-09 US$6.430 -1.68% 98,745
  1. Stock Market
  2. Stocks
  3. BOLT Stock